ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Benitec Biopharma Inc. (BNTC) stock surged +10.65%, trading at $12.42 on NASDAQ, up from the previous close of $11.22. The stock opened at $10.64, fluctuating between $10.61 and $12.45 in the recent session.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Employees | 16 |
Beta | 0.92 |
Sales or Revenue | $216.00K |
5Y Sales Change% | -0.995% |
Fiscal Year Ends | June |
Sector | Healthcare |
Industry | Biotechnology |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com